

LIST OF TABLES

Table No.	Title	Page
Table 2.1:	Definitions of lung volumes and capacities describing pulmonary ventilation	16
Table 2.2:	Factors that may affect the pulmonary absorption rate and bioavailability	23
Table 2.3:	Commercially available DPIs and new DPIs currently under development and its dispersion mechanism	26
Table 2.4:	US FDA requirements for testing Dry Powder Inhalers	34
Table 2.5:	Major modes of liposomal action and related applications	49
Table 3.1:	Calibration for estimation of Phosphatidyl Choline (Stewart assay)	87
Table 3.2:	Calibration for estimation of Cholesterol (Zlatkis, Zak and Boyle's method)	90
Table 3.3:	Calibration curve for Isoniazid in methanol	91
Table 3.4:	Calibration curve for Rifampicin in methanol	95
Table 4.1:	Optimization of liposomal INH preparation by TFH method	109
Table 4.2:	Optimization of liposomal INH preparation by REV method	110
Table 4.3:	Optimization of liposomal RFP preparation by TFH method	113
Table 4.4:	Optimization of liposomal RFP preparation by REV method	114
Table 4.5:	Selection of process parameters by TFH method for INH and RFP liposomes	120
Table 4.6:	Effect process and formulation variables on trans-membrane loading of INH	129
Table 4.7:	Trapped volumes of liposomal dispersions prepared with optimal process and formulation variables	132
Table 4.8:	Particle size range of liposomal batches at various stages of preparation	132
Table 5.1:	Selection and optimization of cryoprotectant for efficient lyophilization of INH liposomes	142
Table 5.2:	Selection and optimization of cryoprotectant for efficient lyophilization of RFP liposomes	143

Table 5.3:	Optimization of INH LDPI formulation	147
Table 5.4:	Optimization of RFP LDPI formulation	148
Table 5.5:	Characterization of LDPI formulations	160
Table 5.6:	Particle size range of rehydrated LDPI formulations	162
Table 5.7:	Essential formulation components of the LDPI batches selected for the further studies	169
Table 6.1:	Stability data of INH70 LDPI formulation	178
Table 6.2:	Stability data of INH71 LDPI formulation	179
Table 6.3:	Stability data of RFP70 LDPI formulation	180
Table 6.4:	Stability data of RFP71 LDPI formulation	181
Table 7.1:	Comparative in vitro drug diffusion of Optimized LDPI formulations	197
Table 7.2:	Regression coefficient of the line of percent drug released Vs square root of time	198
Table 7.3:	Mean flux and Diffusion coefficient values of optimized liposomal formulations across artificial membrane	198
Table 8.1:	Drug level in biological samples following instillation of INH plain drug and liposomal DPI	208
Table 8.2:	Drug level in biological samples following instillation of RFP plain drug and liposomal DPI	210
Table 8.3:	Comparative pharmacokinetic assessment parameters of LDPI formulations to plain drug	212
Table 8.4:	Comparative serum levels of SGOT, SGPT and ALP	212